U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.26 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.14 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -1.53 (-2.86%)
     
  • Gold

    1,827.70
    -23.70 (-1.28%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3583
    -0.0108 (-0.79%)
     
  • USD/JPY

    103.8710
    +0.0550 (+0.05%)
     
  • BTC-USD

    36,620.56
    -1,218.08 (-3.22%)
     
  • CMC Crypto 200

    700.51
    -34.64 (-4.71%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results

·5 min read

- Conference Call and Webcast Today, August 5 at 4:30 p.m. EDT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2020. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6856804.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6856804.

Selected Recent Events

  • Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study

  • Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis

  • Completed dosing in healthy volunteer cohorts in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNAi therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis

  • Completed dosing of the first sequential cohort and collected the first 6-month repeat biopsy in the AROAAT2002 study, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease

  • Completed planned enrollment and dosing of 93 subjects in AROANG1001, a Phase 1/2 clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic being developed for the treatment of mixed dyslipidemia

  • Completed planned enrollment and dosing of 80 subjects in AROAPOC31001, a Phase 1/2 clinical study of ARO-APOC3, the company’s investigational RNAi therapeutic being developed for the treatment of hypertriglyceridemia, and expanded the study to include up to 112 subjects

Selected Fiscal 2020 Third Quarter Financial Results

ARROWHEAD PHARMACEUTICALS, INC.

CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)

Three Months Ended June 30,

Nine Months Ended June 30,

OPERATING SUMMARY

2020

2019

2020

2019

REVENUE

$

27,375,778

$

42,696,636

$

80,359,211

$

125,502,807

OPERATING EXPENSES

Research and development

32,573,134

19,291,710

85,390,086

57,662,381

General and administrative expenses

10,748,506

4,809,177

38,008,836

16,287,841

TOTAL OPERATING EXPENSES

43,321,640

24,100,887

123,398,922

73,950,222

OPERATING INCOME (LOSS)

(15,945,862

)

18,595,749

(43,039,711

)

51,552,585

OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES

2,334,649

1,739,959

6,919,200

4,717,359

NET INCOME (LOSS)

$

(13,611,213

)

$

20,335,708

$

(36,120,511

)

$

56,269,944

NET INCOME (LOSS) PER SHARE (DILUTED)

$

(0.13

)

$

0.21

$

(0.36

)

$

0.58

WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)

101,843,436

98,884,744

100,184,216

97,814,019

FINANCIAL POSITION SUMMARY

June 30,

September 30,

2020

2019

CASH AND CASH EQUIVALENTS

$

219,322,617

$

221,804,128

SHORT-TERM INVESTMENTS

67,709,263

36,899,894

LONG-TERM INVESTMENTS

177,529,881

44,175,993

TOTAL CASH RESOURCES (CASH AND INVESTMENTS)

464,561,761

302,880,015

OTHER ASSETS

91,166,311

46,965,422

TOTAL ASSETS

555,728,072

349,845,437

TOTAL CURRENT DEFERRED REVENUE

26,274,362

77,769,629

TOTAL LONG TERM DEFERRED REVENUE

-

5,035,142

OTHER LIABILITIES

36,868,505

23,004,414

TOTAL LIABILITIES

63,142,867

105,809,185

TOTAL STOCKHOLDERS' EQUITY

492,585,205

244,036,252

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

555,728,072

$

349,845,437

SHARES OUTSTANDING

102,250,872

95,506,271

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005880/en/

Contacts

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com

Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com